Ocugen, Inc. (OCGN)
After hours:
| Previous close | 1.6300 |
| Open | 1.6300 |
| Bid | 1.6200 x 1900 |
| Ask | 1.6500 x 2800 |
| Day's range | 1.5800 - 1.6600 |
| 52-week range | 0.3450 - 2.1050 |
| Volume | |
| Avg. volume | 6,216,322 |
| Market cap | 422.061M |
| Beta (5Y monthly) | 3.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2300 |
| Earnings date | 19 Aug 2024 - 23 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.67 |
GlobeNewswireOcugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the third cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a novel modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-
ZacksIs Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?
Here is how Ocugen (OCGN) and Organon (OGN) have performed compared to their sector so far this year.
- GlobeNewswire
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial• DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial recently convened and
